PrEP for HIV prevention: how it works, who it suits, how to start.

PrEP stands for pre-exposure prophylaxis: medicine taken before any possible exposure to HIV, so that if the virus enters the body it is far less likely to take hold. CDC describes it as medicine, as pills or shots, that reduces your chance of getting HIV, for adults and adolescents without HIV who may be exposed through sex or injection drug use (Preventing HIV with PrEP, CDC, 2026).

There is more than one kind. WHO currently recommends oral tenofovir-based PrEP, a dapivirine vaginal ring, and two long-acting injections, cabotegravir and lenacapavir (HIV fact sheet, WHO, 2026). Which ones are available, and how each is taken, depends on where you live and on your clinician.

PrEP is prevention for people who do not have HIV. It is not a vaccine, and it is not the same as HIV treatment, although some of the same medicines are used for both. Nor is it PEP, the emergency medicine someone takes after a possible exposure, which CDC says must start within 72 hours (Preventing HIV with PEP, CDC, 2024). PrEP is the planned, ongoing option; PEP is the fallback when something unplanned happens.

Very well, with one condition: taking it as prescribed. CDC recommends taking oral PrEP every day, and estimates that taking it daily or consistently reduces the risk of getting HIV by about 99% among men who have sex with men. Its evidence summary defines consistent use, in the studies, as at least four doses a week and says that appears to give similar protection, while daily use stays the recommended schedule. It also notes that when people took PrEP daily or consistently, new HIV infections were extremely rare, with only three confirmed cases worldwide at the time it was written among people whose adherence was verified (HIV risk and prevention estimates, CDC, 2024).

For heterosexual men and women, there is no estimate yet for daily or consistent use. Studies of people who had recently taken PrEP found an 88% to 90% reduction, and CDC expects consistent daily use to be more effective than that, likely similar to what is seen in men who have sex with men (CDC, 2024).

It takes time to reach full protection. For daily pills, CDC says maximum protection arrives after about 7 days for receptive anal sex and about 21 days for receptive vaginal sex, and that there are no data for the insertive partner. Injections follow their own timelines (CDC, 2026). The NHS gives a shorter 7-day figure for vaginal sex with daily PrEP, but that page was last reviewed in March 2023 (NHS), so ask your own clinician exactly when you are protected.

Missed doses matter. CDC explains that if PrEP is not taken as prescribed there may not be enough medicine in the bloodstream to block the virus. Some people use PrEP only around the times they have sex, known as on-demand PrEP; CDC notes this approach has been studied in gay and bisexual men but is not FDA-approved or CDC-recommended, so it is strictly a conversation for your clinician.

CDC says you may be a good candidate for PrEP if you do not have HIV and, in the past six months, you have had anal or vaginal sex and you have a sexual partner with HIV (especially one with an unknown or detectable viral load), have not consistently used a condom, or have been diagnosed with an STI. People who inject drugs and share equipment, and people who have needed PEP more than once, are included too (CDC, 2026).

The NHS describes a similar group, including anyone who has condomless sex with partners whose HIV status they do not know (NHS). In the lifestyle, that description can fit people who meet new partners and do not always use condoms, which is exactly why PrEP is worth knowing about.

CDC also says plainly that you may choose to take PrEP even if none of those situations apply to you. It is a personal prevention choice, not a label. PrEP is for women as well as men: CDC’s guidance covers anyone without HIV who may be exposed through sex, and it can be used while trying to conceive, during pregnancy and while breastfeeding.

CDC calls PrEP safe to take. Some people have diarrhea, nausea, headache, tiredness or stomach pain, and people on injections can have pain where the shot is given. These side effects usually go away over time; tell your clinician about any that are severe or do not settle (CDC, 2026). The NHS lists a similar set and says they usually go away after the first couple of weeks (NHS).

Two common worries have clear answers. CDC says there are no known interactions between PrEP and hormonal birth control such as the pill, patch, ring, shot, implant or IUD, and no known drug conflicts between PrEP and hormone therapy. It is safe to use both at the same time.

This is the most important limit to understand. In CDC’s words, PrEP “reduces the chance of getting HIV but doesn’t prevent other STIs or pregnancy” (CDC, 2026). The NHS says the same (NHS). Chlamydia, gonorrhea, syphilis, herpes and HPV are all outside its reach.

So PrEP works best alongside the rest of the toolkit. Condoms, which CDC describes as highly effective against HIV, gonorrhea and chlamydia (Preventing HIV, CDC, 2024). Regular testing, which the follow-up visits make easy. Vaccines for hepatitis B and HPV. And, for some gay and bisexual men and transgender women, doxy-PEP for bacterial STIs. Our guide to STD risk per act shows how the layers add up.

In the US, CDC says most insurance plans and state Medicaid programs cover PrEP, and that under the Affordable Care Act PrEP must be free under almost all health insurance plans, including the clinic visits and lab tests needed to keep your prescription. Without insurance, manufacturer and state assistance programs can provide free or lower-cost PrEP, and CDC’s PrEP page includes a locator for finding a provider near you (CDC, 2026).

In the UK, PrEP is available from a health professional at an NHS sexual health clinic (NHS). Elsewhere, a local sexual health service is the place to ask; WHO recommends PrEP as an additional prevention option and advises people to seek a clinician’s advice when considering it (WHO, 2026).

Costs and coverage rules change, so confirm the details with your insurer, pharmacist or clinic before you rely on any of them.

PrEP protects the person taking it. If a new partner mentions they are on PrEP, that tells you they are protecting themselves against HIV; it is not protection you are taking, and it says nothing about other STIs. It is a good sign that someone takes their sexual health seriously, and a reason to keep talking rather than a reason to skip condoms.

Whether to mention your own PrEP use is your decision. Many people in the lifestyle talk about testing, protection and boundaries before they play, and PrEP fits naturally into that conversation. Nobody is owed your medical details, and nobody should be judged for taking a medicine that protects them.

Keep health and identity separate. On any platform, identity verification confirms who someone is; it does not verify HIV status, PrEP use or test results. Share dated results directly with partners if you choose to, and never send them to a platform. For the wider picture of how health, consent and event etiquette fit together, start with our play-safe guide.